William Dai named one of GrowthCap's Top 25 Healthcare Investors of 2022

Congrats William!

Apexigen Publicly Listed Post-Business Combination

2022 SVB Report Results

Devoro Medical Reaches Acquisition Agreement with Boston Scientific!

Apexigen Announces New Data from Phase 1/2 Trial

Luminopia Announces Oversubscribed Seed Extension Round

Apexigen Publicly Listed Post-Business Combination

Skyhawk Collaboration with Sanofi

GrowthCap Top 25 Healthcare Investors - William Dai

William Dai named one of GrowthCap's Top 25 Healthcare Investors of 2022

Apexigen to go public via SPAC merger

Huma.AI Series A & Product Update

2022 SVB Report Results

Robert Kamen joins ShangBay Capital as our newest Senior Advisor